Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

53 54 Next >

Uncovering Dividend Opportunities with NYSE:NVS. ↗

August 23, 2024

Balancing Dividends and Fundamentals: The Case of NOVARTIS AG-SPONSORED ADR (NYSE:NVS).

Via Chartmill

2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200 ↗

August 18, 2024

These companies' growth paths should only be briefly interrupted by headwinds.

Via The Motley Fool

Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug ↗

August 13, 2024

Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-selling heart-failure drug. The decision pressures Novartis to explore...

Via Benzinga

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

August 12, 2024

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and...

Via Newsfile

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

August 08, 2024

Via Investor Brand Network

Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR. ↗

August 07, 2024

The question on everyone's mind: Will NOVARTIS AG-SPONSORED ADR breakout?

Via Chartmill

Why NYSE:NVS is a Top Pick for Dividend Investors. ↗

August 02, 2024

Why the dividend investor may take a look at NOVARTIS AG-SPONSORED ADR (NYSE:NVS).

Via Chartmill

Novartis Reports Near 40% Margin In Q2; Shares Slide ↗

July 18, 2024

Novartis topped Q2 views and lifted guidance. Shares eased after a four-month run.

Via Investor's Business Daily

FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease ↗

August 08, 2024

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression....

Via Benzinga

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs ↗

August 06, 2024

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

Via Benzinga

Topics Lawsuit

Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

August 06, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END

Via FinancialNewsMedia

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

August 06, 2024

From FN Media Group LLC

Via GlobeNewswire

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

July 30, 2024

From Arvinas Inc.

Via GlobeNewswire

AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife ↗

July 23, 2024

The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.

Via Benzinga

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗

July 19, 2024

The Nasdaq tumbled amid chip woes.

Via Investor's Business Daily

Pharma Leader Beats on Earnings, But Shares Fall

July 19, 2024

Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug.

Via MarketBeat

Topics Intellectual Property

Novartis Ag (NVS) Q2 2024 Earnings Call Transcript ↗

July 18, 2024

NVS earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Why Novartis Stock Is Down Today Despite Topping Q2 Estimates ↗

July 18, 2024

Investors were caught off guard by a decision on the research and development front.

Via The Motley Fool

VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? ↗

July 18, 2024

It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...

Via Benzinga

Topics Stocks

Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs ↗

July 18, 2024

Novartis reports strong Q2 results with adjusted EPS of $1.97, up 21% YoY, and sales at $12.51 billion, up 11%. Key drivers include Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio, and Pluvicto. The...

Via Benzinga

Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens ↗

July 18, 2024

Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly repo

Via Benzinga

Topics Economy

Alnylam Stock Is a Blockbuster Biopharma In the Making ↗

July 18, 2024

Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.

Via InvestorPlace

NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q2 2024 ↗

July 18, 2024

NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

2 Magnificent Stocks to Buy With $500 ↗

July 18, 2024

These reliable healthcare companies look attractive no matter how you slice it.

Via The Motley Fool

D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday ↗

July 18, 2024

Via Benzinga

3 Global Stocks to Buy to Escape the Volatility on Wall Street ↗

July 16, 2024

Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times.

Via InvestorPlace

3 Spinoff Stocks You Should Buy Now: July 2024 ↗

July 15, 2024

Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early.

Via InvestorPlace

The 7 Most Undervalued Healthcare Stocks to Buy in July 2024 ↗

July 13, 2024

Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector.

Via InvestorPlace

3 Healthcare Stocks Injecting AI for Big Gains ↗

July 13, 2024

Investors should keep a close eye on these AI healthcare stocks as they revolutionize the future of drug development and patient care.

Via InvestorPlace

Topics Artificial Intelligence

Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years ↗

July 15, 2024

Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today